Kenvue Inc. operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands. The Skin Health and Beauty segment provides face and body care, hair, sun, and other care products under the Neutrogena, Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Rogaine, and OGX brand names. The Essential Health segment offers oral and baby, women's health, wound, and other care products under the Listerine, Johnson's, Band-Aid, and Stayfree, o.b., tampons, Carefree, and Desitin Diaper Rash brands. The company was incorporated in 2022 and is headquartered in Skillman, New Jersey.

Kenvue Inc.

Key Points
Kenvue was spun off from Johnson & Johnson in mid-2023, and its life is starting out a little rough.
Pfizer is working through typical drug industry issues, but there's a notable dividend risk to consider.
Omega Healthcare has proven it is a reliable dividend stock, and it's getting back on the growth track.
A big dividend yield is nice to see, but it shouldn't be the only thing you look at when buying a stock. The actual business behind the yield is, in fact, more important. That's why you'll need to think carefully about your risk tolerance when you look at high-yielding healthcare stocks like Kenvue (NYSE: KVUE), Pfizer (NYSE: PFE), and Omega Healthcare (NYSE: OHI). Here's a quick review of all of these high-yield healthcare stocks.
Kenvue gets off on the wrong foot
Kenvue was spun off from Johnson & Johnson (NYSE: JNJ) in mid-2023. It basically owns its former parent's over-the-counter products. It is more like a consumer staples company than a healthcare company in many ways, even though it sells things like Tylenol. Tylenol is notable right now because it was just highlighted as a potential risk if taken during pregnancy. That led investors to dump the stock.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »
On top of that, the healthcare-focused consumer staples maker is also performing a bit poorly right now. In the second quarter of 2025, sales fell 4% and organic sales dropped 4.2%. Adjusted earnings came in at $0.29 per share, down from $0.32 in the same quarter of 2024. It isn't shocking for a newly separated business to have some issues as it starts out its new, stand-alone life. And given the generally stable nature of consumer staples products, it is probably worth giving the company the benefit of the doubt.
But at the same time, the stock has fallen notably, and the yield has risen to a rather high 5.5%. The average dividend yield for a consumer staples stock is 2.7%. If you can handle some near-term uncertainty and have a contrarian streak, Kenvue may be of interest to you. Just go in recognizing that there isn't much of a dividend track record to go on here (though it is worth noting that its former parent is a Dividend King).
Pfizer is doing what needs to be done
Pfizer is one of the oldest and most respected pharmaceutical companies in the world. It has proven that it knows how to survive in what is a very technologically complicated and competitive business. Yet the stock has a huge 6.9% yield right now as it faces down some typical industry headwinds.
There are perception issues around drugmakers that are a hindrance today. But Pfizer is working to get back into favor, noting that it recently inked a deal with the U.S. government to make sizable capital investments in the country, keep consumer costs low, and avoid tariff issues. In addition, the company recently inked a deal to buy Metsera (NASDAQ: MTSR) to bolster its drug pipeline. That's an effort to offset the expected hit from a patent cliff the company is facing and was necessitated by Pfizer's lack of success with its own pipeline of drug candidates.
However, dealing with the government and patents is just normal for the drug industry. Still, the high yield highlights a real risk. Pfizer cut its dividend when it acquired Wyeth back in 2009. With the payout ratio hovering in the 90% range, which is high, the board of directors might choose to cut the dividend again as it completes its Metsera deal. It is probably best to view Pfizer as a turnaround story, noting that the stock price has fallen nearly 60% since late 2021. If the dividend holds, it is icing on the cake.
3. Omega Healthcare stood tall through the storm
Omega Healthcare is going to be the easiest stock for dividend investors to love on this list. The company is a senior-housing-focused real estate investment trust (REIT). The dividend yield is an attractive 6.6%. But the big story is around what happened to the dividend during the coronavirus pandemic.
That period of time was particularly difficult for senior housing assets, since the elderly were most at risk and COVID-19 spread most easily in group settings. Omega had to deal with a large number of tenants who couldn't pay their rent. That process is nearly over -- and here's the impressive part -- the dividend was sustained right through all of it. Many peers resorted to dividend cuts. In fact, Omega is starting to grow again, with over half a billion dollars in assets acquired in the second quarter of 2025 alone.
The worst is over, and now Omega can get back to more normal operations. Only buy it if you don't mind investing in an industry that was in the news in a bad way just recently. That said, this REIT is offering a huge dividend yield and is, frankly, one of the cleanest dirty shirts in the senior housing niche.
Don't just look at yield when buying these stocks
Kenvue, Pfizer, and Omega are all interesting dividend stocks with high yields. But you need to dig into each of the stories before you hit the buy button. Of the trio, Omega is probably the least risky choice, given how well it survived the pandemic. Kenvue is a bit of an unknown, but its business is fairly stable despite some post-J&J separation wobbles. And Pfizer is almost certain to survive and thrive, but what happens to the dividend is less clear, given the company's dividend history.
Should you invest $1,000 in Pfizer right now?
Before you buy stock in Pfizer, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Pfizer wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $590,357!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,141,748!*
Now, it’s worth noting Stock Advisor’s total average return is 1,033% — a market-crushing outperformance compared to 193% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.
*Stock Advisor returns as of October 20, 2025
Reuben Gregg Brewer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Kenvue and Pfizer. The Motley Fool recommends Johnson & Johnson and recommends the following options: long January 2026 $13 calls on Kenvue. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

3 Healthcare Stocks Paying the Highest Dividends of 2025

Key Points
Kenvue owns Johnson & Johnson's former over-the-counter brands.
Medtronic has a diversified medical-device portfolio and is closing in on "Dividend King" status.
Pfizer has a lofty yield as it faces fairly normal industry headwinds.
Dividend investors shouldn't be dissuaded from investing just because the S&P 500 (SNPINDEX: ^GSPC) has a miserly 1.2% yield. If you dig in a bit, you can find attractive dividend stocks, including in the growth-oriented healthcare sector. Three you might want to consider right now are Kenvue (NYSE: KVUE), Medtronic (NYSE: MDT), and (with a grain of salt) Pfizer (NYSE: PFE). Here's what you need to know.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »
1. Kenvue is a boring consumer-staples business
Kenvue was created when it was spun off from "Dividend King" Johnson & Johnson. (A Dividend King is a company that has raised its dividend annually for 50-plus consecutive years.) That left J&J operating a drug and medical-device company and Kenvue operating J&J's over-the-counter business.
Kenvue is a consumer-staples company, with iconic brands like Band-Aid, Johnson's Shampoo, Aveeno, and Tylenol. However, right now, that last brand has gotten a lot of negative attention after it was singled out by members of the Trump administration as presenting a potential health issue for the baby if taken during pregnancy.
That attention has resulted in Kenvue's stock price plunging. The stock price drop pushed the dividend yield up to 5.5%.
It is still a young business, for sure, but Kenvue has a strong stable of brands and products to which customers are loyal. This isn't a fly-by-night company, and the negativity probably represents an emotional pendulum swing that's gone too far. It's true that the business hasn't been performing particularly well in 2025 and recently lowered its full-year guidance, but even good brands go through weak periods.
It seems highly likely that this consumer-staples company will muddle through this period in one piece while continuing to reward investors for sticking around. That, by the way, is exactly what former parent J&J has provided for decades. A $1,000 investment will get you around 66 shares of Kenvue stock.
2. Medtronic is closing in on a big dividend achievement
Johnson & Johnson is a Dividend King because it has increased its dividend for over five decades. Medtronic's streak is at 48 years, so it's just two years shy of that incredible achievement. The company isn't planning to fall short, noting that it specifically stated that a planned business spinoff of its diabetes division won't lead to a change in its dividend policy.
The spinoff, however, is part of an important business overhaul. Medtronic, which makes medical devices, has been working through a period of slow growth. Now it has new products coming out and is looking to focus on only its most profitable businesses.
Diabetes doesn't have the same margins as the rest of the company, and the spinoff is expected to be instantly accretive to earnings. This spinoff and other changes being made should position the company for stronger growth in the years ahead.
That said, Wall Street is taking a show-me attitude. Medtronic's yield is a historically elevated 3% or so. If you like fairly boring dividend stocks, $1,000 will net you around 10 shares of Medtronic while the company works to get back into investors' good graces.
3. Pfizer is a high-risk/high-reward dividend stock
Pfizer has the highest yield here at nearly 7%. However, the dividend-payout ratio is hovering worryingly close to 100%.
The pharmaceutical giant has cut its dividend before, specifically following the large acquisition of Wyeth. Given that it's again working on a big acquisition of Metsera, there's a risk that the dividend gets a haircut.
When you add upcoming patent expirations to the list of issues, you can see why investors are worried. But Pfizer is one of the largest and most resilient drug companies on the planet, and what's happening to the business right now isn't unusual for a drug company.
If you shift your view and look at it as a turnaround stock, it could be worth buying. The high yield, in this case, is simply a sign that the stock is deeply unloved today. But even if there's a dividend cut, a dividend is likely to continue being paid. If history is any guide, the dividend will start to grow again after a reset.
The Metsera acquisition is actually a sign that the company is doing what it needs to do to get back on track. Simply put, Pfizer wasn't having enough success with its own drug pipeline, so it bought a company with more promising drug candidates. It was the right move and a statement to the company's long-term staying power. A $1,000 commitment here will allow you to buy roughly 40 shares.
Three options, from low risk to high risk
If you want a boring high-yield healthcare stock that's on the cusp of being a Dividend King, Medtronic is for you. If you don't mind a little uncertainty, Kenvue's consumer-staples business could be interesting, even as the company deals with some business headwinds. For turnaround lovers, Pfizer's high yield is a sign that Wall Street isn't fond of the drugmaker, even though it has proven that it will do what's necessary to be a long-term survivor.
Should you invest $1,000 in Kenvue right now?
Before you buy stock in Kenvue, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Kenvue wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $590,357!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,141,380!*
Now, it’s worth noting Stock Advisor’s total average return is 1,033% — a market-crushing outperformance compared to 193% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.
*Stock Advisor returns as of October 20, 2025
Reuben Gregg Brewer has positions in Medtronic. The Motley Fool has positions in and recommends Kenvue and Pfizer. The Motley Fool recommends Johnson & Johnson and Medtronic and recommends the following options: long January 2026 $13 calls on Kenvue, long January 2026 $75 calls on Medtronic, and short January 2026 $85 calls on Medtronic. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Got $1,000? 3 High-Yield Healthcare Stocks to Buy and Hold Forever.

The NASDAQ 100 After Hours Indicator is up 4.16 to 25,145.18. The total After hours volume is currently 131,009,346 shares traded.
The following are the most active stocks for the after hours session:
SoFi Technologies, Inc. (SOFI) is +0.06 at $28.74, with 7,464,776 shares traded. SOFI's current last sale is 124.96% of the target price of $23.
Amazon.com, Inc. (AMZN) is unchanged at $216.48, with 3,791,949 shares traded. As reported by Zacks, the current mean recommendation for AMZN is in the "buy range".
Kinder Morgan, Inc. (KMI) is unchanged at $27.52, with 3,756,303 shares traded.KMI is scheduled to provide an earnings report on 10/22/2025, for the fiscal quarter ending Sep2025. The consensus earnings per share forecast is 0.28 per share, which represents a 25 percent increase over the EPS one Year Ago
Aurora Innovation, Inc. (AUR) is unchanged at $5.32, with 3,135,740 shares traded. As reported in the last short interest update the days to cover for AUR is 7.829046; this calculation is based on the average trading volume of the stock.
Nu Holdings Ltd. (NU) is +0.02 at $15.43, with 2,769,577 shares traded. As reported by Zacks, the current mean recommendation for NU is in the "buy range".
Oklo Inc. (OKLO) is +0.5259 at $159.58, with 2,716,514 shares traded. OKLO's current last sale is 187.74% of the target price of $85.
Hewlett Packard Enterprise Company (HPE) is unchanged at $22.87, with 2,571,697 shares traded. HPE's current last sale is 84.7% of the target price of $27.
Stride, Inc. (LRN) is -0.53 at $145.06, with 2,502,933 shares traded. As reported by Zacks, the current mean recommendation for LRN is in the "buy range".
Kenvue Inc. (KVUE) is unchanged at $14.96, with 2,378,198 shares traded. KVUE's current last sale is 72.98% of the target price of $20.5.
Invesco QQQ Trust, Series 1 (QQQ) is +0.46 at $612.00, with 2,261,430 shares traded., following a 52-week high recorded in today's regular session.
Robinhood Markets, Inc. (HOOD) is unchanged at $135.80, with 2,098,852 shares traded. Over the last four weeks they have had 4 up revisions for the earnings forecast, for the fiscal quarter ending Sep 2025. The consensus EPS forecast is $0.49. As reported by Zacks, the current mean recommendation for HOOD is in the "buy range".
NVIDIA Corporation (NVDA) is +0.25 at $182.89, with 1,962,378 shares traded. As reported by Zacks, the current mean recommendation for NVDA is in the "buy range".
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

After Hours Most Active for Oct 20, 2025 : SOFI, AMZN, KMI, AUR, NU, OKLO, HPE, LRN, KVUE, QQQ, HOOD, NVDA

Key Points
Kenvue was spun off from Johnson & Johnson and is offering a lofty 5.1% yield.
General Mills is a food giant with a 5% yield.
Realty Income is the largest net lease REIT and offers a 5.4% yield.
The S&P 500 (SNPINDEX: ^GSPC) has a tiny little yield of just below 1.2%. You can do way better than that with companies like Kenvue (NYSE: KVUE), General Mills (NYSE: GIS), and Realty Income (NYSE: O), all of which have yields of at least 5%. If that sounds interesting to you as October rolls along, here's a quick look at each of these high-yield dividend stocks.
1. Kenvue is facing a publicity crisis
Kenvue is often listed on the Dividend King list because it was spun off from Dividend King Johnson & Johnson (NYSE: JNJ) in mid-2023. It owns the over-the-counter health products that J&J used to produce, including things like Johnson's baby shampoo, Aveeno, Listerine, and Tylenol (more on this brand in a second), among many others. As a stand-alone business, it obviously only has a short history. That said, the dividend was increased in 2024 and again in 2025, so it is following the tradition of its former parent. Long-term dividend investors should probably assume that slow and steady dividend growth is the plan.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »
Kenvue is facing an unusual public relations crisis at the moment. The U.S. government has made claims that Tylenol may be a potential health concern during pregnancy. The stock has fallen dramatically, pushing the dividend yield up to a lofty 5.1% for what is, basically, a diversified consumer staples business with a large portfolio of industry-leading brands. There are risks here, since Kenvue has, for the moment, become a story stock. News flow will have an outsized effect on the shares until this issue passes. However, for more aggressive contrarian investors, this could be an opportunistic time to buy Kenvue.
2. General Mills is starting an investment year
General Mills isn't hiding the problems it faces. Fiscal first-quarter 2026 sales fell 7%, with organic sales down 3%. That's not good, but the company isn't sitting still and doing nothing. It has been warning investors that fiscal 2026 will be an investment year, in which the food maker will be increasing its spending on things like advertising and innovation. In fact, it's going to be something of a kitchen sink year, since the divestiture of the company's yogurt operations is going to be a drag on performance, as well. Periods like this happen.
Despite a very long and successful history of navigating the consumer staples sector and customer buying trends, General Mills' shares have been hard hit. The dividend yield has been pushed up to 5%. But while the dividend isn't getting increased every year, it has trended generally higher over the long term. Sure, quarterly earnings are likely to be rough reading in fiscal 2026, but that could be signaling a long-term opportunity for income investors to pick up a company that is a valuable partner to retailers, offering people the well-known brands they trust.
3. Realty Income is the net lease giant
Last up here is Realty Income, which has a roughly 5.4% dividend yield right now. The company has increased its dividend annually for three decades at a slow and steady pace of 4.2%, annualized. That's about what you should expect over the long term from this large net lease real estate investment trust (REIT), which is basically built from the ground up to be a reliable dividend stock.
A net lease requires the tenant to pay most property-level expenses, freeing Realty Income from the cost and hassle of maintaining its properties. That said, it is the largest competitor in its niche, with over 15,600 properties, exposure to retail and industrial assets, among others, and a portfolio that spans the United States and Europe. Add in an investment grade rated balance sheet, and Realty Income has proven that it can live up to its trademarked nickname, "The Monthly Dividend Company."
Unlike the other two stocks here, Realty Income doesn't come with any near-term caveats. It's just a reliable, high-yield stock that even the most conservative income investors should probably consider buying today.
Don't get discouraged by the market's yield
The S&P 500 index is the de facto market measure, but markets are made up of many different businesses. If you dig beneath the surface of the market with a focus on dividend yield, you will find plenty of attractive income opportunities. Some of the most interesting ones today include Kenvue, General Mills, and Realty Income. Take the time to get to know these three stocks, and you may find you want to add one, or more, to your portfolio today.
Should you invest $1,000 in Kenvue right now?
Before you buy stock in Kenvue, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Kenvue wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $646,805!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,123,113!*
Now, it’s worth noting Stock Advisor’s total average return is 1,055% — a market-crushing outperformance compared to 189% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.
*Stock Advisor returns as of October 13, 2025
Reuben Gregg Brewer has positions in General Mills and Realty Income. The Motley Fool has positions in and recommends Kenvue and Realty Income. The Motley Fool recommends Johnson & Johnson and recommends the following options: long January 2026 $13 calls on Kenvue. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

3 Dividend Stocks With 5% (or Higher) Yields to Buy Hand Over Fist in October

Key Points
Kenvue is battling a barrage of ailments.
The company has a new leadership team to help turn things around.
Multiple catalysts could drive a recovery in the coming year.
Kenvue (NYSE: KVUE) isn't a household name. The consumer health products company has been around in its current form for only a couple of years. However, while you might not know the name Kenvue, you've probably heard of some of its many products, which include Band-Aid, Listerine, and Tylenol.
Shares of the consumer products company have tumbled more than 20% this year due to a variety of issues, including concerns linking Tylenol to autism. That slump has driven its dividend yield up to more than 5%.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now, when you join Stock Advisor. See the stocks »
While Kenvue stock is down this year, it could soar in 2026. Here are a few of the catalysts that could drive a recovery in the consumer healthcare company.
Meet Kenvue
Kenvue began to take shape in late 2022 when Johnson & Johnson (NYSE: JNJ) unveiled the new name for its former consumer healthcare business, which it was transforming into a stand-alone public company. The name comes from the words "ken," which means knowledge, and "vue," which references sight. Johnson & Johnson ultimately completed an initial public offering (IPO) of the business in 2023. The companies officially separated later that year when Johnson & Johnson completed an exchange offer with its shareholders, giving them control over the newly independent company.
Kenvue is one of the world's largest consumer healthcare product companies. It owns a portfolio of leading consumer healthcare product brands focused on self-care (e.g., Tylenol and Band-Aid), skin health and beauty (e.g., Aveeno and Neutrogena), and essential health (e.g., Listerine). The company reported nearly $15.5 billion in sales last year and recorded over $1 billion in profit.
While Kenvue owns a global portfolio of iconic consumer healthcare products, innovation is part of its DNA. It has launched over 100 new product innovations annually since 2020.
The initial struggle
Johnson & Johnson believed that Kenvue could thrive as a stand-alone company. The business was delivering solid organic revenue growth as more consumers around the world relied on its consumer health products for their daily lives. Johnson & Johnson expected Kenvue to deliver improved profit margins, as the independent company could operate more effectively. Meanwhile, an independent Kenvue would have more flexibility to pursue acquisitions to further enhance its global portfolio and growth profile.
Unfortunately, things haven't played out that way. Kenvue has struggled to grow its sales (they were flat last year and down 4% in the second quarter of 2025). Meanwhile, instead of growing its profit margins, its earnings have tumbled due to higher costs and other factors.
Things have gone from bad to worse this year after the Trump administration linked Tylenol usage by expectant mothers to autism and attention-deficit/hyperactivity disorder. Those concerns have weighed heavily on the stock.
Taking action to get back on track
Kenvue's problems have drawn the attention of activist investors. Starboard Value pressed the company to make changes, which it has done by refreshing the board and bringing in a new senior leadership team. The company hired a new CFO in May and brought in a new interim CEO a couple of months later.
The new management team is working with advisors to explore strategic alternatives for the company. Those options could include optimizing the brand portfolio and enhancing its operating performance to boost growth, as well as other initiatives to unlock shareholder value. Among the things the company is considering is the sale or spinoff of its skin health business.
Selling off pieces of the company could unlock shareholder value. For example, analysts believe that the skin health and beauty unit could be worth between $6 billion and $9 billion. Selling that division to a rival consumer health products company or a private equity fund would provide it with the cash to bolster its balance sheet and potentially facilitate acquisitions to enhance its remaining business units. A sale of this unit at or above the high end of that range could provide a big boost to Kenvue's stock price.
Meanwhile, tangible actions that drive a growth reacceleration and improve its profitability would also give the shares a boost in the coming year. Additionally, positive news regarding Tylenol would also be a major upside catalyst.
Healthy upside potential
Kenvue has gotten off to a rocky start as an independent public company. However, activist investors have pushed for change, resulting in a refreshed board, a new senior leadership team, and a renewed strategic focus on unlocking value. Those actions could help drive a rebound in the share price next year. That upside potential makes Kenvue an enticing turnaround candidate. In the meantime, investors will get paid well while they wait for the company to execute its turnaround strategy.
Should you invest $1,000 in Kenvue right now?
Before you buy stock in Kenvue, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Kenvue wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $646,805!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,123,113!*
Now, it’s worth noting Stock Advisor’s total average return is 1,055% — a market-crushing outperformance compared to 189% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.
*Stock Advisor returns as of October 13, 2025
Matt DiLallo has positions in Johnson & Johnson and Kenvue and has the following options: short December 2025 $16 puts on Kenvue. The Motley Fool has positions in and recommends Kenvue. The Motley Fool recommends Johnson & Johnson and recommends the following options: long January 2026 $13 calls on Kenvue. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Meet the 5%-Yielding Dividend Stock That Could Soar in 2026

Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in Boeing Co. (Symbol: BA), where a total of 52,901 contracts have traded so far, representing approximately 5.3 million underlying shares. That amounts to about 61.5% of BA's average daily trading volume over the past month of 8.6 million shares. Especially high volume was seen for the $180 strike put option expiring November 14, 2025, with 4,541 contracts trading so far today, representing approximately 454,100 underlying shares of BA. Below is a chart showing BA's trailing twelve month trading history, with the $180 strike highlighted in orange:
DaVita Inc (Symbol: DVA) saw options trading volume of 3,982 contracts, representing approximately 398,200 underlying shares or approximately 51.6% of DVA's average daily trading volume over the past month, of 771,430 shares. Especially high volume was seen for the $135 strike call option expiring November 21, 2025, with 1,976 contracts trading so far today, representing approximately 197,600 underlying shares of DVA. Below is a chart showing DVA's trailing twelve month trading history, with the $135 strike highlighted in orange:
And Kenvue Inc (Symbol: KVUE) saw options trading volume of 185,310 contracts, representing approximately 18.5 million underlying shares or approximately 45.2% of KVUE's average daily trading volume over the past month, of 41.0 million shares. Particularly high volume was seen for the $17 strike call option expiring November 21, 2025, with 45,105 contracts trading so far today, representing approximately 4.5 million underlying shares of KVUE. Below is a chart showing KVUE's trailing twelve month trading history, with the $17 strike highlighted in orange:
For the various different available expirations for BA options, DVA options, or KVUE options, visit StockOptionsChannel.com.
Also see:
Top Ten Hedge Funds Holding IOAC
BLBD shares outstanding history
ENH Options Chain
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Notable Friday Option Activity: BA, DVA, KVUE

The iShares ESG MSCI USA Leaders ETF is seeing unusually high volume in afternoon trading Friday, with over 316,000 shares traded versus three month average volume of about 30,000. Shares of SUSL were up about 0.1% on the day.
Components of that ETF with the highest volume on Friday were Nvidia, trading off about 0.4% with over 84.0 million shares changing hands so far this session, and Intel, up about 0.7% on volume of over 68.8 million shares. Kenvue is the component faring the best Friday, up by about 8.6% on the day, while Newmont is lagging other components of the iShares ESG MSCI USA Leaders ETF, trading lower by about 7.1%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Friday's ETF with Unusual Volume: SUSL

In trading on Friday, the iShares Global Consumer Staples ETF is outperforming other ETFs, up about 1.3% on the day. Components of that ETF showing particular strength include shares of Kenvue, up about 8.8% and shares of Colgate-palmolive, up about 1.9% on the day.
And underperforming other ETFs today is the Global X Silver Miners ETF, off about 8.1% in Friday afternoon trading. Among components of that ETF with the weakest showing on Friday were shares of New Pacific Metals, lower by about 17%, and shares of Gold Resource, lower by about 14.8% on the day.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Friday's ETF Movers: KXI, SIL

In early trading on Friday, shares of Kenvue topped the list of the day's best performing components of the S&P 500 index, trading up 5.6%. Year to date, Kenvue has lost about 30.2% of its value.
And the worst performing S&P 500 component thus far on the day is State Street, trading down 4.9%. State Street is showing a gain of 9.5% looking at the year to date performance.
Two other components making moves today are Oracle, trading down 4.4%, and American Express, trading up 3.9% on the day.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

S&P 500 Movers: STT, KVUE

The S&P 500 Index ($SPX) (SPY) on Thursday closed down -0.63%, the Dow Jones Industrials Index ($DOWI) (DIA) closed down -0.65%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed down -0.36%. December E-mini S&P futures (ESZ25) fell -0.68%, and December E-mini Nasdaq futures (NQZ25) fell -0.41%.
Stock indexes gave up an early advance on Thursday and retreated after regional bank stocks tumbled due to concerns about credit quality, which fueled long liquidation and risk-off sentiment in the stock market. Zions Bancorp sank by more than 13% and Western Alliance Bancorp dropped by more than 10% to drag regional bank stocks lower after they disclosed problems with loans involving allegations of fraud.
Join 200K+ Subscribers: Find out why the midday Barchart Brief newsletter is a must-read for thousands daily.
Stocks initially moved higher on Thursday as strong technology earnings boosted market sentiment. Optimism that AI spending will continue to rise is pushing stocks higher today after Taiwan Semiconductor Manufacturing Co., the world’s most advanced semiconductor manufacturer and chipmaker for Apple and Nvidia, raised its projections for 2025 revenue growth for the second time this year. This underscored the strength in global AI spending.
Dovish Fed comments on Thursday knocked T-note yields lower and also supported stocks. The 10-year T-note yield dropped to a 6.25-month low of 3.97% on Thursday after Fed Governor Christopher Waller said the Fed can continue to lower interest rates in quarter-percentage-point increments to support a faltering labor market. Also, Richmond Fed President Tom Barkin said US productivity growth seems to be improving “significantly,” possibly containing any inflationary impacts from trade tariffs.
Thursday’s US economic news was mixed for stocks. On the negative side, the Oct Philadelphia Fed business outlook survey fell -36.0 to a 6-month low of -12.8, weaker than expectations of 10.0. Conversely, the Oct NAHB housing market index rose +5 to a 6-month high of 37, stronger than expectations of 33.
The escalation of trade tensions between the US and China, along with the ongoing US government shutdown, has sparked a buying spree in precious metals as a haven, with gold and silver reaching fresh all-time highs today.
The shutdown of the US government continues, weighing on market sentiment and delaying key economic reports. The government shutdown means delays in the release of government reports, including the last three weeks of weekly initial unemployment claims, the Aug US trade report, and the Sep payroll report. Last Friday, the Bureau of Labor Statistics (BLS) said the September consumer price report, which was originally scheduled to be released on Wednesday, will be released on October 24. The White House has warned that if the government shutdown lingers, it would trigger widespread dismissals of employees in government programs that don’t align with President Trump’s priorities. Bloomberg Economics estimates that 640,000 federal workers will be furloughed during the shutdown, which would expand jobless claims and push the unemployment rate up to 4.7%.
The markets this week will focus on earnings results as the Q3 earnings season begins. Rising corporate earnings expectations are a bullish backdrop for stocks. According to Bloomberg Intelligence, 78% of the S&P 500 companies that have reported so far have beaten forecasts. Also, more than 22% of companies in the S&P 500 that provided guidance for their Q3 earnings results are expected to beat analysts’ expectations, the highest in a year. However, Q3 profits are expected to have risen by +7.2% y/y, the smallest increase in two years. Also, Q3 sales growth is projected to slow to +5.9% y/y from 6.4% in Q2.
The markets are pricing in a 100% chance of a -25 bp rate cut at the next FOMC meeting on Oct 28-29.
Overseas stock markets settled higher on Thursday. The Euro Stoxx 50 closed up +0.84%. China’s Shanghai Composite closed up +0.10%. Japan’s Nikkei Stock 225 closed up +1.27%.
Interest Rates
December 10-year T-notes (ZNZ5) on Thursday closed up +16.5 ticks. The 10-year T-note yield fell -5.2 bp to 3.976%. Dec T-notes recovered from early losses on Thursday and rallied to a 5-week high, and the 1-year T-note yield dropped to a 6.25-month low of 3.967%.
T-notes rallied Thursday due to dovish Fed comments. Fed Governor Christopher Waller said the Fed can continue to lower interest rates to support a faltering labor market, and Richmond Fed President Tom Barkin stated that US productivity growth appears to be improving “significantly.” T-notes also found support after the Oct Philadelphia Fed business outlook survey fell more than expected to a 6-month low, and after inflation expectations fell when the 10-year breakeven inflation rate dropped to a 5-month low of 2.270%. T-notes surged to their highs on Thursday afternoon when regional bank stocks plummeted due to concerns about credit quality, sparking safe-haven demand for T-notes.
T-notes also have support from the ongoing US government shutdown, which could lead to additional job losses, reduced consumer spending, and a weakened US economy, potentially allowing the Fed to continue cutting interest rates.
European government bond yields were mostly lower on Thursday. The 10-year German bund yield was unchanged at 2.570%. The 10-year UK gilt yield dropped to a 3.25-month low of 4.496% and finished down -4.2 bp to 4.501%.
UK Aug manufacturing production rose +0.7% m/m, stronger than expectations of +0.2% m/m
ECB Governing Council member Wunsch said, “I would say that the probability that the ECB cuts interest rates again has been receding over the last few weeks or months.”
Swaps are discounting a 2% chance for a -25 bp rate cut by the ECB at its next policy meeting on October 30.
US Stock Movers
Regional bank stocks tumbled on Thursday, led by a -13% decline in Zions Bancorp (ZION) and a -10% slide in Western Alliance Bancorp (WAL) after they disclosed problems with loans involving allegations of fraud. Zions Bancorp announced that it will record a $60 million provision and charge-off of $50 million after legal action was initiated by banks and other lenders related to two commercial and industrial loans extended by a bank division. Also, Citizens Financial Group (CFG) closed down more than -6%, and Regions Financial (RF), KeyCorp (KEY), Truist Financial (TFC), and Huntington Bancshares (HBAN) closed down more than -5%.
Kenvue Inc (KVUE) closed down more than -13% to lead losers in the S&P 500 after Citigroup published a research note flagging a “major” lawsuit in the UK related to the use of baby powder that could cause financial implications for the company.
Hewlett Packard Enterprise (HPE) closed down more than -10% after projecting 2026 earnings of $2.20 to $2.40 a share, weaker than the consensus of $2.41.
F5 Inc (FFIV) closed down more than -10%, adding to Wednesday’s -3% loss, after a potentially “catastrophic” breach of the cybersecurity provider blamed on state-backed hackers from China, with the hackers gaining “long-term, persistent access” to certain systems and stealing files, including source code.
Marsh & McLennan Cos (MMC) closed down more than -8% after reporting Q3 adjusted operating margin of 22.7%, below the consensus of 22.9%.
Verisk Analytics (VRSK) closed down more than -6% to lead losers in the Nasdaq 100 after Rothschild & Co Redburn downgraded the stock to sell from neutral with a price target of $220.
Travelers Cos (TRV) closed down more than -2% to lead losers in the Dow Jones Industrials after reporting Q3 net premiums written of $11.47 billion, below the consensus of $11.84 billion.
Lululemon Athletica (LULU) closed down more than -1% after Bernstein downgraded the stock to market perform from outperform.
Chipmakers and AI infrastructure stocks moved higher Thursday after Taiwan Semiconductor Manufacturing Co., the world’s most advanced semiconductor manufacturer and chipmaker for Apple and Nvidia, raised its projections for 2025 revenue growth for the second time this year. As a result, Micron Technology (MU) closed up more than +5% to lead gainers in the Nasdaq 100, and ON Semiconductor (ON) closed up more than +5%. Also, Western Digital (WDC) closed up by more than +4% and Seagate Technology Holdings Plc (STX) closed up by more than +3%. In addition, Nvidia (NVDA), Analog Devices (ADI), KLA Corp (KLAC), and Arista Networks (ANET) closed up more than +1%.
Gold mining stocks rallied on Thursday after the price of COMEX gold climbed to a new record high. As a result, Kinross Gold (KGC), Barrick Mining (B), Newmont (NEM), Gold Fields Ltd (GFI), and Anglogold Ashanti Plc (AU) closed up more than +2%.
Praxis Precision Medicines (PRAX) closed up more than +183% after two studies in its Phase 3 Essential3 program of ulixacaltamide to treat tremors met their primary endpoints.
JB Hunt Transport Services (JBHT) closed up more than +22% to lead gainers in the S&P 500 after reporting Q3 revenue of $3.05 billion, stronger than the consensus of $3.02 billion.
Knight-Swift Transportation Holdings (KNX) closed up more than +6% after Bank of America upgraded the stock to buy from neutral with a price target of $50.
Salesforce (CRM) closed up more than +3% to lead gainers in the Dow Jones Industrials after projecting revenue growth will accelerate to double digits in the coming years, and announced it will purchase an additional $7 billion of shares in the next six months.
Snap-on Inc (SNA) closed up more than +3% after reporting Q3 EPS of $5.02, stronger than the consensus of $4.64.
Earnings Reports(10/17/2025)
Ally Financial Inc (ALLY), American Express Co (AXP), Comerica Inc (CMA), Fifth Third Bancorp (FITB), Huntington Bancshares Inc/OH (HBAN), Regions Financial Corp (RF), SLB Ltd (SLB), State Street Corp (STT), Truist Financial Corp (TFC), Webster Financial Corp (WBS).
On the date of publication, Rich Asplund did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
More news from Barchart
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.